

SHARE OWNERSHIP DISPUTE – FURTHER INFORMATION

Melbourne 8 April 2008: On 3 April 2008 Acrux (ASX: ACR) announced that it had been informed that the ownership of one substantial shareholding in the Company was in dispute as a result of the collapse of Opes Prime. On 7 April 2008, Australia and New Zealand Banking Group Limited announced that it had beneficial title to 14.5 million Acrux shares (approximately 9% of the issued share capital of Acrux), of which ANZ Nominees Limited is the registered holder. These shares represent the holding of Acrux non-executive director Ross Dobinson and his associated entities. The ownership of the shares remains in dispute.

About Acrux - www.acrux.com.au

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.
- Acrux has one product, Estradiol MDTS[®] (EvaMist[™] or Ellavie[™]) to treat menopause symptoms, approved by the US FDA and has the following products in clinical development:
 - Testosterone MD-Lotion[®] to treat testosterone deficiency in men
 - Testosterone MDTS[®] to treat decreased libido in women
 - Nestorone[®] MDTS[®] contraceptive sprays for women
 - An undisclosed companion animal health product
 - Fentanyl MDTS[®] to treat chronic pain
 - Nicotine MDTS[®] for smoking cessation
- Acrux has licensed worldwide rights to its technology for selected contraceptives and for an undisclosed proprietary drug to ORGANON, USA rights for Estradiol MDTS[®] to KV Pharmaceutical and for Testosterone MDTS[®] to VIVUS, and AUS/NZ distribution rights for Estradiol MDTS[®] to Aspen Pharmacare and for Testosterone MDTS[®] and Fentanyl MDTS[®] to CSL Limited. Acrux has also licensed its technology to Eli Lilly and Company for veterinary healthcare products.